Clinical trials: Drug Drug Interaction Study
Healthy
Amoxicillin Drug Interaction Study With MMX® Mesalazine/Mesalamine
This is a drug interaction study evaluating the pharmacokinetic profiles of amoxicillin administered alone \& in combination with MMX Mesalazine/mesalamine.
- Trial name
- NCT01442688
- Testing
- Amoxicillin + MMX mesalazine/mesalamine
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Shire
Pharmacokinetics
Drug - Drug Interaction Study Between Quinine Sulfate and Theophylline
In a prior in vitro study using human hepatocytes quinine was shown to induce the activity of Cytochrome p450 CYP 1A2. The present study will evaluate the extent to which quinine sulfate-related induction of this enzyme effects…
- Trial name
- NCT00779259
- Testing
- Theophylline 300mg, Quinine 648 mg, Theophylline 300 mg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.
Healthy
An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects
To date, no study has investigated whether there is a drug interaction between the protease inhibitor fosamprenavir and the integrase inhibitor raltegravir.
- Trial name
- NCT00802074
- Testing
- Raltegravir, Fosamprenavir, Ritonavir
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Garden State Infectious Disease Associates, PA
Drug Interaction, Analgesics
Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder
The purpose of this research study is to test the safety, tolerability, drug interactions with buprenorphine-naloxone, and effectiveness lemborexant when used to treat Opioid Use Disorder.
- Conditions
- Drug Interaction, Analgesics, Opioid Use Disorder
- Trial name
- NCT04818086
- Testing
- Lemborexant, Buprenorphine-naloxone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Virginia Commonwealth University
Hyperphosphatemia, Chronic Kidney Disease
Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects
The primary objective is to assess the effects of colestilan on the pharmacokinetic profile of candesartan cilexetil when administered at the same time as, 1 hour before, and 3 hours after the first daily dose of colestilan…
- Trial name
- NCT01976572
- Testing
- colestilan, candesartan
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Healthy Volunteers
A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants
The purpose of this study is to determine the effect of baricitinib on the levels of digoxin in the blood stream and how long it takes the body to remove digoxin.
- Trial name
- NCT01859078
- Testing
- Baricitinib, Digoxin
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Haematological Malignancies
Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies
The purpose of the study is to the evaluate safety, tolerability, pharmacokinetics (PK), and efficacy of AZD0466 as monotherapy in partciapants with advanced haematological malignancies and also to assess drug-drug interaction…
- Trial name
- NCT04865419
- Testing
- AZD0466, Voriconazole
- Where
- 15 sites in United States, Australia and 4 more
- Volunteers
- 46 people
- Sponsor
- AstraZeneca
Healthy
Drug-Drug Interaction Study: ASP2151 and Ritonavir
ASP2151 is an experimental treatment for herpes. HIV infected people are susceptible to contracting other infections because of their compromised immune system.
- Trial name
- NCT02223351
- Testing
- ASP2151, ritonavir
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Maruho Europe Limited
Healthy
Drug-drug Interaction Study of Aggrenox and Omeprazole in Normal Volunteers
The objective of the current study is to investigate if a drug-drug interaction occurs with the administration of omeprazole 80 mg q.d.
- Trial name
- NCT01303445
- Testing
- Aggrenox alone, Aggrenox and omeprazole, Omeprazole alone
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Coronary Artery Disease, Drug Interaction Potentiation
Ranitidin Versus Omeprazole in Patients Taking Clopidogrel
Previous reports have shown a possible drug interaction between clopidogrel and proton pump inhibitors (PPI´s), which could result in increased number of adverse cardiovascular events among patients on dual antiplatelet…
- Trial name
- NCT01896557
- Testing
- omeprazole, Ranitidine, Clopidogrel
- Volunteers
- 92 people
- Sponsor
- University of Sao Paulo General Hospital
Healthy Participants
Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants
The purpose of this study is to estimate the effect PF-07321332/Ritonavir and Ritonavir on Midazolam (a cytochrome P450 [CYP]3A4 substrate) in Healthy Adult Participants.
- Trial name
- NCT05032950
- Testing
- Midazolam, PF-07321332/ritonavir + Midazolam, Ritonavir + Midazolam
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pharmacokinetics
Drug-Drug Interaction Between Colchicine and Verapamil ER
Colchicine is a substrate for both cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp). Verapamil hydrochloride is a potent inhibitor of cytochrome P450 (CYP) 3A4 and P-gp.
- Trial name
- NCT00983242
- Testing
- Colchicine, Verapamil HCl ER
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.
Lymphoma, Advanced Cancer
A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma
The purpose of this study was to assess the effect of tasisulam as an inhibitor of CYP2C9, using tolbutamide as a probe substrate. This study was to have 3 treatment periods, and continued access in an extension period.
- Trial name
- JZAR (NCT01185548)
- Testing
- Tolbutamide, Tasisulam
- Where
- 5 sites in United Kingdom
- Volunteers
- 4 people
- Sponsor
- Eli Lilly and Company
Hyperkalaemia
Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects
This study will be an open-label, randomised sequence, 2-period, 2-cohort, 2-treatment in each cohort, cross-over study in healthy subjects (males and females of non-childbearing potential), performed at a single study centre.
- Trial name
- NCT04788641
- Testing
- Tacrolimus, Cyclosporin, Sodium Zirconium Cyclosilicate
- Where
- Germany
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Metronidazole Drug Interaction Study With MMX® Mesalazine/Mesalamine
Drug interaction study evaluating the pharmacokinetic profiles of Metronidazole administered alone \& in combination with MMX® Mesalazine/mesalamine
- Trial name
- NCT01418365
- Testing
- Metronidazole + MMX Mesalazine/mesalamine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Shire
Healthy Volunteers
Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants
The main purpose of this study is to learn about how itraconazole and rifampin affect LOXO-305 in healthy participants. Participation could last about 8 weeks.
- Trial name
- NCT05134337
- Testing
- LOXO-305, Itraconazole, Rifampin
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Loxo Oncology, Inc.
Healthy Volunteers
A Study to Test the Effects of Itraconazole and Carbamazepine on OPC-167832 in Healthy Men and Women
The purpose of this trial is to assess the potential for cytochrome P450 (CYP)-mediated drug-drug interactions (DDIs) with OPC-167832.
- Trial name
- NCT07542847
- Testing
- OPC-167832, Itraconazole, Carbamazepine
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors
The purpose of this study is to characterize the effect of repeat-dose administration of brigatinib 180 milligram (mg) once daily (QD) on the single-dose pharmacokinetics (PK) of midazolam.
- Trial name
- NCT03420742
- Testing
- Midazolam, Brigatinib
- Where
- 14 sites in France, Italy and 2 more
- Volunteers
- 24 people
- Sponsor
- Takeda
Drug Interaction
Evaluation of Vamorolone CYP3A4 Induction on Midazolam (a Sensitive CYP 3A4 Substrate) Pharmacokinetics
The purpose of this study was to investigate how vamorolone affects the CYP3A4 enzyme in humans by measuring the pharmacokinetics of midazolam and its metabolite, 1'-hydroxymidazolam, in healthy subjects.
- Trial name
- NCT06689527
- Testing
- Vamorolone, Midazolam
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Santhera Pharmaceuticals
Healthy Volunteers
Drug Interaction With Proton Pump Inhibitors for Nifedipine ER Tablets
The purpose of this study is to measure the amount of study drug present in blood after being administered a generic version of nifedipine extended-release tablets, 60 mg (Valeant Pharmaceuticals, LLC) and brand-name version…
- Trial name
- NCT03100838
- Testing
- Nifedipine 60 MG Extended Release Oral Tablet, omeprazole/sodium bicarbonate, SmartPill (TM)
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Food and Drug Administration (FDA)